Dr. Heinz Wiendl
Professor
Neurology
University of Munster
Germany
Biography
1989-1996: Studies in Psychology and Medicine, Universities of Erlangen, Basel and Duke; 1996-97: Residency program at the Department of Neurology, University Erlangen-Nürnberg; 1997: Approbation; 1997-1998: Research Fellow at the Institute of Anatomy and Neuro-Anatomy II, University Erlangen-Nürnberg (Prof. Lütjen-Drecoll); 1998-2000: Research Fellow Max-Planck-Institute for Neurobiology, Department of Neuroimmunology in Martinsried (Prof. H. Wekerle, Prof. R. Hohlfeld) (Scholarship granted by the Deutsche Forschungsgemeinschaft (DFG)); 2000-2004: Clinical and research fellow in the Hertie-Institute for Brain Research, Department of Neurology, University of Tübingen (Prof. J. Dichgans); 2004: Head of a junior research group for Neuroimmunology, University of Tübingen (IZKF Tübingen); 2005-2010: Professor of Neurology (C3), Head of Clinical Research Group for Multiple Sclerosis and Neuroimmunology, Department of Neurology, University of Würzburg (Prof. Toyka); 2010-2013: Professor W 3 and Chair, Department of Neurology, Inflammatory diseases of the nervous system and neurooncology, University of Münster; 2013: Professor W 3 and Chair, Department of Neurology University of Münster; 2013: Dean for Research and Young Scientists of the medical faculty Münster; 2015: Member of the commission „Perspectives in neurology“ of the DGN; 2016: Speaker of the DFG funded transregional co-operative research centre (TR-CRC) “Mutiple Sclerosis“ (evaluated 03/2016); 2016: Expert Committee for cellular neurosciences at the DFG; 2016: Representative of the academia in the supervisory board of the UKM; 2016: Member of the International Society of Neurosciences (ISNI); 2016: Member of the ISNI’s International Advisory Board
Research Interest
Neuroinflammation and neuro immunology; Immune Regulation in MS and autoimmune nervaus system disorders; lnflammatory mechanisms of neurodegenation; Immune mediated mechanisms of neurodegeneration; Immune cell trafficking into the CNS; Biomarkers and biosignatures (related to MS, immune therapy and its adverse effects); Development of biomarkers
Publications
-
Eckert B, Wiendl H, Schramm P, Fiehler J, Kemmling A, et al. (2016) Computed tomography-based quantification of lesion water uptake identifies patients within 4.5 hours of stroke onset: A multicenter observational study. Ann Neurol 80: 924-934.
-
Stenzel W, Budde T, Wiendl H, Bittner S, Meuth SG, et al. (2016) The potassium channels TASK2 and TREK1 regulate functional differentiation of murine skeletal muscle cells. Am J Physiol Cell Physiol 311: C583-C595.
-
Engel DR, Roth J, Kuhlmann T, Wiendl H, Klotz L, et al. (2016) The farnesoid-X-receptor in myeloid cells controls CNS autoimmunity in an IL-10-dependent fashion. Acta Neuropathol (Berl)132: 413-431.
-
Wiendl H, Pankratz S, Meltzer J, Farwick N, Greune L, et al. (2017) Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. Oncoimmunology 6: e1250050.
-
Miske R, Gross CC, Scharf M, Golombeck KS, Hartwig M, et al. (2017) Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration. Neurol Neuroimmunol Neuroinflamm 4: e307.
